RITUXIMAB IN SUBJECTS WITH ISN/RPS CLASS III OR IV LUPUS NEPHRITIS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是比较利妥昔单抗联合霉酚酸酯(MMF)与安慰剂联合MMF治疗狼疮性肾炎的安全性和有效性。利妥昔单抗是一种单抗，它是一种帮助保护身体免受外来物质伤害的蛋白质。它可以减少体内某些类型的B细胞，而B细胞可能在炎症中起重要作用。 利妥昔单抗已经用于少数狼疮性肾炎患者，这项研究旨在进一步评估利妥昔单抗是否会减少狼疮和狼疮性肾炎的体征和症状。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to investigate the safety and efficacy of rituximab in combination with mycophenolate mofetil (MMF) compared with placebo in combination with MMF in the treatment of lupus nephritis. Rituximab is a monoclonal antibody, which is a protein that helps protect the body against foreign materials. It decreases some types of B-cells in the body which may be important in inflammation. Rituximab has been used in a small number of patients with lupus nephritis, and this study is designed to further evaluate whether rituximab would reduce the signs and symptoms of lupus and lupus nephritis.